Phase 2b Controlled Study of Dosing Techniques - Part B
NCT ID: NCT07161011
Last Updated: 2025-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2025-09-08
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2b Controlled Study
NCT07140380
IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
NCT06400459
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
NCT05992922
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
NCT00404131
A Multi-Center Study Subjects With Dry Eye Syndrome
NCT01745887
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IVW-1001 0.2%
Ophthalmic Eyelid wipe
IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Low dose
IVW-1001 0.4%
Ophthalmic Eyelid Wipe
IVW-1001 Ophthalmic Eyelid Wipe 0.4%
High dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Low dose
IVW-1001 Ophthalmic Eyelid Wipe 0.4%
High dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BCVA +0.70 logarithm of minimum angle of refraction (Snellen equivalent 20/100) or better in each eye at the Screening Visit
* For women of childbearing potential, confirmed negative pregnancy test at the Screening Visit, not nursing a child, and willing to comply with one of the acceptable methods of birth control described in the protocol
* History (by subject recollection) of artificial tear use within 30 days prior to the Screening Visit
* Unanesthetized Schirmer's test score 5-19 mm inclusive in at least 1 eye (same eye) at the Screening Visit and the Baseline Visit
Exclusion Criteria
* IOP ≥23 mmHg in either eye at either the Screening Visit or the Baseline Visit
* History of glaucoma or ocular hypertension in either eye requiring past or current medical or surgical intervention
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IVIEW Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eye Research Foundation
Newport Beach, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IVW-1001-CS-202B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.